<DOC>
	<DOCNO>NCT01362348</DOCNO>
	<brief_summary>The purpose 12 week , open-label study investigate safety efficacy single dose regimen pazopanib eye drop neovascular AMD .</brief_summary>
	<brief_title>12 Week Patient Study Neovascular Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>MD7114987 Phase 2a study design determine whether pazopanib eye drop potential reduce retinal edema maintain improve visual acuity person previously untreated subfoveal choroidal neovascularization ( CNV ) lesion secondary age-related macular degeneration ( AMD ) characterize safety tolerability pazopanib eye drop administer 12-week period .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Subjects eligible enrolment study must meet following criterion : Consent : Subject understands procedure , agree participate study ( include participation CFH Y402H pharmacogenetic research ) , sign date informed consent form prior initiation studyrelated activity . If subject unable read consent form due visual impairment consent must read subject verbatim person administer consent , family member , legally acceptable representative . ( Note : Consent legally acceptable representative allow accordance local law , regulation , ethic committee policy . ) Agerelated macular degeneration : For subject enrol study , one eye ( study eye ) treat , eligibility criterion apply study eye . All following characteristic require must confirm central reading center : CNV cause AMD extend geometric center foveal avascular zone Center subfield thickness ( inclusive subretinal fluid ) &gt; 320 micron OCT [ SPECTRALIS® ( Heidelberg ) ] Total lesion area ≤12 disc area fluorescein angiography , lesion complex include CNV , blood , block florescence blood , serous detachment retinal pigment epithelium CNV comprise &lt; 50 % lesion area classic CNV comprise &lt; 50 % lesion area fibrosis comprise ≤ 25 % lesion area evidence classic CNV , presume recent disease progression base deterioration ( ≥ 5 letter decrease vision evidence growth CNV lesion fluorescein angiography ) within last 3 month evidence hemorrhage CNV Visual acuity : Bestcorrected visual acuity score electronic ETDRS study eye 25 73 letter ( approximately equivalent Snellen VA 20/320 20/32 ) screen Gender age : Subject male female adult 50 year age old . Nonchildbearing potential : Female subject nonchildbearing potential define physiologically incapable become pregnant . This include female postmenopausal ( 12 month spontaneous amenorrhea ) surgically postmenopausal ( via document hysterectomy bilateral tubal ligation ) . In questionable case postmenopausal status , blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MIU/mL estradiol &lt; 40 pg/mL ( &lt; 140 pmol/L ) [ equivalent value base local laboratory criterion ] confirmatory . Refer SPM information . Study Compliance : Subject able willing comply study requirement able willing attend schedule visit . Liver function test : Subject liver chemistry value within normal limit clinically insignificant evidence serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2xULN ; alkaline phosphatase bilirubin &lt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable , bilirubin fractionate direct bilirubin &lt; 35 % ) . QT interval : Subject QTcF value &lt; 450 msec , &lt; 480 msec subject Bundle Branch Block . [ Note : subject pace rhythm may consider pending discussion medical monitor . ] Subjects meeting follow criterion must enrol study : Study Eye : Additional eye disease study eye could compromise bestcorrected visual acuity ( e.g . glaucoma document visual field loss , clinically significant diabetic retinopathy , ischemic optic neuropathy , infection retinitis pigmentosa ) CNV study eye due cause unrelated agerelated macular degeneration Presence retinal angiomatous proliferation ( RAP ) study eye , determine investigator ( confirmation indocyanine green angiography require ) Geographic atrophy involve center fovea study eye Anterior segment vitreous abnormality study eye would preclude adequate observation fundus photograph , fluorescein angiography spectraldomain OCT Vitreous , subretinal retinal hemorrhage study eye unrelated AMD Presence RPE tear study eye Aphakia total absence posterior capsule ( Yttrium aluminum garnet ( YAG ) capsulotomy permit ) study eye History vitrectomy study eye Intraocular surgery study eye within 3 month prior treatment Any previous treatment study eye neovascular AMD , approve investigational Fellow Eye : Current intravitreal antiVEGF therapy fellow eye Bestcorrected visual acuity score electronic ETDRS &lt; 56 letter fellow eye screen Concurrent Conditions Concomitant Medications : Subject uncontrolled glaucoma ( intraocular pressure &gt; 25 mmHg ) despite treatment antiglaucoma medication . A known , positive test Hepatitis B surface antigen Hepatitis C antibody within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Active bleed disorder history hemoptysis , cerebral clinically significant gastrointestinal hemorrhage within 6 month screen Significant uncontrolled unstable cardiovascular , nervous system , pulmonary , renal , endocrine , gastrointestinal disease example : Uncontrolled diabetes mellitus , hemoglobin A1c ( HbA1c ) &gt; 10 % Myocardial infarction stroke within 6 month screen Major surgery within 3 month screen Clinically relevant thyroid disease Uncontrolled hypertension : Systolic blood pressure &gt; 160 mmHg Diastolic blood pressure &gt; 100 mmHg Note : Initiation adjustment antihypertensive medication permit prior study entry provide referenced criterion meet ( See Section 4.4.3 ) . Subject history within past 2 year alcohol substance abuse , psychiatric disorder likely confound efficacy safety assessment . Known HIV infection Within 6 month prior Screening Visit , use systemically administer anti angiogenic agent ( e.g. , bevacizumab , sunitinib , cetuximab , sorafenib , pazopanib ) , approve investigational Within 6 month prior Screening Visit , use medication know toxic retina , lens optic nerve ( e.g . desferoximine , chloroquine/hydrochloroquine , chlorpromazine , phenothiazine , tamoxifen , ethambutol ) Use systemic steroid ( &gt; 10 mg prednisone equivalent/day ) within 14 day start treatment Use prohibit medication within restrict timeframe relative start study medication ( See Section 5.5.2 ) Use investigational drug within 30 day screen History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation A condition situation , , opinion investigator , may result significant risk patient , confound study result interfere significantly participation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Age-related Macular Degeneration</keyword>
</DOC>